Stefani Wolff's Net Worth
$2.77 Million
Who is Stefani Wolff?
Stefani Wolff has an estimated net worth of $2.77 Million. This is based on reported shares across multiple companies, which include Rain Oncology Inc., Nurix Therapeutics, Inc., and Principia Biopharma Inc..
SEC CIK
Stefani Wolff's CIK is 0001751790
Past Insider Trading and Trends
2022 was Stefani Wolff's most active year for acquiring shares with 7 total transactions. Stefani Wolff's most active month to acquire stocks was the month of December. 2020 was Stefani Wolff's most active year for disposing of shares, totalling 16 transactions. Stefani Wolff's most active month to dispose stocks was the month of August. 2019 saw Stefani Wolff paying a total of $25,003.71 for 65,505 shares, this is the most they've acquired in one year. In 2020 Stefani Wolff cashed out on 280,070 shares for a total of $2,201,645.64, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Rain Oncology Inc. (RAIN) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 26
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Nurix Therapeutics, Inc. (NRIX) Snapshot price: $8.28
EVP and COO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +11.29% | 620 |
$9.88 | -$3,377.69 | 6.11K |
Apr 30 - May 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
| +15.81% | 538 |
$11.78 | -$4,994.55 | 3.94K |
Jan 30
| |||
Form 4
| +21.94% | 612 |
$12.88 | -$4,508.17 | 3.4K |
Oct 30 - Oct 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 9
| |||
Form 4
| +95.89% | 606 |
$15.67 | -$5,578.52 | 1.24K |
Jul 30 - Aug 1
| |||
Form 4
|
∞
| 632 |
$11.75 | -$3,877.50 | 632 |
Apr 30 - May 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Principia Biopharma Inc. No price found
Chief Development Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -19.10K |
$100.00 | -$1,359,200.00 |
0
|
Sep 18 - Sep 28
| |||
Form 4
| -22.37% | -5.50K |
$60.75 | -$334,384.54 | 19.1K |
Scheduled
|
Jun 15
| ||
Form 4/A
| -18.28% | -5.50K |
$46.15 | -$254,030.55 | 24.6K |
Scheduled
|
Mar 16
| ||
Form 4/A
| -15.46% | -5.50K |
$49.43 | -$272,090.73 | 30.1K |
Scheduled
|
Dec 16
| ||
Form 4
|
—
|
0
|
$25.35 | -$229,031.38 | 35.61K |
Scheduled
|
Mar 16
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 5
| |||
Form 4
|
—
|
0
|
$26.99 | -$247,087.02 | 35.61K |
Scheduled
|
Dec 16
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||